[HTML][HTML] The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatins⃞
DE Telford, BG Sutherland, JY Edwards… - Journal of lipid …, 2007 - ASBMB
The combination of ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein (NPC1L1), and
an HMG-CoA reductase inhibitor decreases cholesterol absorption and synthesis. In clinical
trials, ezetimibe plus simvastatin produces greater LDL-cholesterol reductions than does
monotherapy. The molecular mechanism for this enhanced efficacy has not been defined.
Apolipoprotein B-100 (apoB-100) kinetics were determined in miniature pigs treated with
ezetimibe (0.1 mg/kg/day), ezetimibe plus simvastatin (10 mg/kg/day), or placebo (n …
an HMG-CoA reductase inhibitor decreases cholesterol absorption and synthesis. In clinical
trials, ezetimibe plus simvastatin produces greater LDL-cholesterol reductions than does
monotherapy. The molecular mechanism for this enhanced efficacy has not been defined.
Apolipoprotein B-100 (apoB-100) kinetics were determined in miniature pigs treated with
ezetimibe (0.1 mg/kg/day), ezetimibe plus simvastatin (10 mg/kg/day), or placebo (n …